BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

10 2 2025 07:00:05 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

05 2 2025 10:18:33 提供 NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 2 2025 07:00:08 提供 Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

10 1 2025 07:00:30 提供 Nasdaq GlobeNewswire

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 1 2025 07:00:57 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2025 07:00:46 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 12 2024 16:15:10 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

06 11 2024 07:00:53 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 11 2024 07:00:47 提供 Nasdaq GlobeNewswire

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

04 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

24 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

BioCryst to Report Third Quarter 2024 Financial Results on November 4

21 10 2024 07:00:23 提供 Nasdaq GlobeNewswire

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

14 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

10 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 10 2024 07:00:53 提供 Nasdaq GlobeNewswire

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

02 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

30 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

06 9 2024 02:00:11 提供 Nasdaq GlobeNewswire

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

05 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 9 2024 07:00:46 提供 Nasdaq GlobeNewswire